Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 13/20 | 0.50 |
| ▸ | JAK2 | O60674 | 6/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.42 |
| ▸ | PAK4 | O96013 | 2/20 | 0.38 |
| ▸ | JAK1 | P23458 | 2/20 | 0.37 |
| ▸ | BRD2 | P25440 | 2/20 | 0.36 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2018827 | 1.00 | BRD4 (0.50) | BRD4JAK2PDPK1PAK4JAK1 | |
| SCHEMBL2021185 | 0.86 | BRD4 (0.52) | BRD4JAK2PDPK1PAK4JAK1 | |
| SCHEMBL2021182 | 0.86 | BRD4 (0.52) | BRD4JAK2PDPK1PAK4JAK1 | |
| SCHEMBL2017273 | 0.77 | BRD4 (0.54) | BRD4JAK2PDPK1PAK4BRD2 | |
| SCHEMBL2017271 | 0.77 | BRD4 (0.54) | BRD4JAK2PDPK1PAK4BRD2 | |
| SCHEMBL2016056 | 0.74 | OPRM1 (0.41) | JAK2JAK1OPRM1OPRD1OPRK1 | |
| SCHEMBL2016058 | 0.74 | OPRM1 (0.41) | JAK2JAK1OPRM1OPRD1OPRK1 | |
| SCHEMBL2023548 | 0.70 | PAK4 (0.44) | PAK4JAK1 | |
| SCHEMBL2023550 | 0.70 | PAK4 (0.44) | PAK4JAK1 | |
| SCHEMBL4650409 | 0.64 | PTK2 (0.51) | BRD4JAK2PDPK1PAK4JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2011-06-30 | — | — | US | disclosed |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | BRD4 338/4885JAK2 2/4885PDPK1 116/4885 |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | BRD4 338/4885JAK2 2/4885PDPK1 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.